Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03414918
Other study ID # 4283/AO/17
Secondary ID
Status Not yet recruiting
Phase N/A
First received December 27, 2017
Last updated January 29, 2018
Start date March 2018
Est. completion date January 2020

Study information

Verified date January 2018
Source University Hospital Padova
Contact Gian Paolo Rossi, MD
Phone +39-049-8212263
Email gianpaolo.rossi@unipd.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates if :

1 ) the plasma aldosterone concentration and blood pressure change in response to roxithromycin could be useful for the screening of PA patients carrying a KCNJ5-mutated APA; 2) the change of PAC in response to mutated KCNJ5 channel is truly occurring in KCNJ5-mutated APA.


Description:

Aldosterone-producing adenoma (APA) cause primary aldosteronism (PA), the main curable cause of endocrine hypertension, is in up to 66% of all cases investigated with adrenal vein sampling (AVS). Mutations in the KCNJ5 potassium channel involve up to 70% of APA and cause the most florid PA phenotypes. The recent finding that macrolide antibiotics specifically inhibit in vitro the altered function of mutated KCNJ5 channels has opened new horizons for the diagnosis and treatment of APA with KCNJ5 mutations in that it can allow identification and target treatment of PA patients harbouring a mutated APA. Thus, the aim of the present study was to investigate if clarithromycin and roxithromycin, two macrolides that potently blunt mutated Kir3.4 channel function in vitro, affect plasma aldosterone concentration in adrenal vein blood during AVS and in peripheral blood, respectively, in PA patients with a mutated APA.

The investigators designed two proof of concept studies. In study A: consecutive patients with an unambiguous biochemical evidence of PA will be exposed to a single dose of 250 mg clarithromycin during AVS, to assess its effect on the relative aldosterone secretion index (RASI) in adrenal vein blood from the gland with and without APA. In study B: consecutive hypertensive patients submitted to the work-up for hypertension will receive a single oral dose of 150 mg roxithromycin. The experimental endpoints will be the change induced by roxithromycin of plasma aldosterone concentration (PAC) and other steroids, direct active renin concentration (DRC), serum K+, systolic and diastolic blood pressure.

The investigators expect to prove that: i) clarithromycin allows identification of mutated APA before adrenalectomy and sequencing of tumour DNA; ii) the acute changes of PAC, DRC, and blood pressure in peripheral venous blood after roxithromycin can be a proxy for the presence of an APA with somatic mutations.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 342
Est. completion date January 2020
Est. primary completion date January 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- A signed and dated informed consent form

- A diagnosis of hypertension defined either as:

Use of antihypertensive drug (s) Arterial hypertension: in untreated patients this must be confirmed by daytime ambulatory blood pressure monitoring (ABPM), or home blood pressure monitoring, with blood pressure higher or equal to 135 mmHg for systolic blood pressure and/or higher or equal to 85 mmHg for diastolic blood pressure.

Normal observation of ECG QT interval.

Exclusion Criteria:

- History of allergy/intolerance to any macrolides;

- Refusal of the patient to undergo dynamic testing;

- Refusal of the patient to undergo AVS and/or contraindications to the general anesthesia that is required for laparoscopic adrenalectomy (for objective 2);

- Suspicion of cortisol-aldosterone co-secreting adenoma

- Pregnancy

- Family history of sudden death

- Family history of syncope

- Family history of Long QT syndrome and or torsade de point

- Congenital or drug-induced Long QT syndrome

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clarithromycin
Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).

Locations

Country Name City State
Italy Department of Medicine - DIMED, University of Padova, Italy Padova

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Padova DMG Paris Descartes

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Caroccia B, Prisco S, Seccia TM, Piazza M, Maiolino G, Rossi GP. Macrolides Blunt Aldosterone Biosynthesis: A Proof-of-Concept Study in KCNJ5 Mutated Adenoma Cells Ex Vivo. Hypertension. 2017 Dec;70(6):1238-1242. doi: 10.1161/HYPERTENSIONAHA.117.10226. Epub 2017 Oct 9. — View Citation

Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011 Feb 11;331(6018):768-72. doi: 10.1126/science.1198785. — View Citation

Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F; PAPY Study Investigators. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens. 2007 Jul;25(7):1433-42. — View Citation

Rossitto G, Battistel M, Barbiero G, Bisogni V, Maiolino G, Diego M, Seccia TM, Rossi GP. The subtyping of primary aldosteronism by adrenal vein sampling: sequential blood sampling causes factitious lateralization. J Hypertens. 2017 Sep 27. doi: 10.1097/HJH.0000000000001564. [Epub ahead of print] — View Citation

Scholl UI, Abriola L, Zhang C, Reimer EN, Plummer M, Kazmierczak BI, Zhang J, Hoyer D, Merkel JS, Wang W, Lifton RP. Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma. J Clin Invest. 2017 Jun 30;127(7):2739-2750. doi: 10.1172/JCI91733. Epub 2017 Jun 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Study 1: Change in Relative Aldosterone Secretion Index (RASI). Within-patient change from baseline of the RASI in adrenal vein blood draining the gland with and without the APA. Baseline and after 45min clarithromycin infusion.
Primary Study 2: Change in plasma aldosterone concentration (PAC). Within-patient change from baseline of PAC in peripheral venous blood in patients undergoing screening for PA. Baseline and after 60 and 120 minutes roxitromycin administration
See also
  Status Clinical Trial Phase
Recruiting NCT06008184 - Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
Recruiting NCT02945904 - IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Not yet recruiting NCT00553722 - Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Phase 4
Completed NCT01234220 - Adrenal Vein Sampling International Study (AVIS Study) N/A
Completed NCT00001176 - Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure N/A
Active, not recruiting NCT04605549 - A Study of CIN-107 in Adults With Primary Aldosteronism Phase 2
Not yet recruiting NCT06246357 - Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism Phase 2
Completed NCT02751021 - Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction N/A
Recruiting NCT02832388 - Primary Aldosteronism in Western Norway
Completed NCT00004354 - Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism N/A
Completed NCT01096654 - SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. Phase 3
Completed NCT00155064 - Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism Phase 4
Recruiting NCT03778645 - Adrenal Venous Sampling Via an Antecubital Approach
Recruiting NCT04328181 - Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT) N/A
Active, not recruiting NCT02030587 - Laparoscopic Adrenalectomy Versus Radiofrequency Ablation N/A
Completed NCT01897727 - Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment N/A
Recruiting NCT00451672 - The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Phase 4
Recruiting NCT00407784 - Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives. N/A
Not yet recruiting NCT06192238 - China National Study of Adrenal Venous Sampling